|display ongoing studies|
|Study||Ref.||Design||studied treatment||control treatment||patients||study risk of bias||sample sizes||Results|
COVID-19 prophylaxis (excluding childrens) meta-analysis
|ChAdOx1 phase 3 (AstraZeneca), 2020|
|RCT||Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)||control||COVID-19 prophylaxis (excluding childrens)||some concern||5807/5829||conclusif|
|15 studies excluded by filtering options (5 RCT / 10 OBS)|
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).